CIK 0001841387 · <br>Emerging growth company
Candel Therapeutics, Inc.
Sign in to watch- Ticker
- CADL
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 522214851
- Phone
- 617-916-5445
- Business address
- 117 KENDRICK STREET, SUITE 450, NEEDHAM, MA, 02494
- 4 Planned sale Chief Technology Officer sold 31,278 shares at $8.82 ($275,947)
- 4 Planned sale See Remarks sold 5,000 shares at $8.83 ($44,169)
- 4 Returned to the company 10% owner returned 21,165 shares (to the company)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Returned to the company 10% owner returned 31,335 shares (to the company)
- 4 Open-market sale Chief Scientific Officer sold 13,534 shares at $7.23 ($97,783)
- 4 Open-market sale Chief Technology Officer sold 14,322 shares at $7.23 ($103,476)
- 4 Open-market sale See Remarks sold 9,511 shares at $7.23 ($68,717)
- 4 Open-market sale Chief Executive Officer sold 21,704 shares at $7.23 ($156,811)
- 4 Open-market sale Chief Medical Officer sold 10,428 shares at $7.23 ($75,342)
- 4 Open-market sale Chief Scientific Officer sold 13,673 shares at $8.22 ($112,367)
- 4 Open-market sale See Remarks sold 9,971 shares at $8.22 ($81,944)
- 4 Open-market sale Chief Executive Officer sold 21,172 shares at $8.22 ($173,996)
- 4 Open-market sale Chief Technology Officer sold 14,545 shares at $8.22 ($119,534)
- 4 Open-market sale Chief Medical Officer sold 10,799 shares at $8.22 ($88,749)
- 4 Returned to the company 10% owner returned 200,000 shares (to the company)
Page 4 of 11 · 202 filings